Clone TIF3C5 is most commonly used in vivo in mice as a neutralizing antibody to block endogenous mouse interferonalpha (IFNα), allowing researchers to study the biological and antiviral roles of IFNα during viral infections and immune responses.

Key in vivo applications in mice include:

• Neutralization of mouse IFNα: TIF3C5 specifically recognizes and binds to several murine IFNα subtypes (IFNαA, 1, 4, 5, 11, and 13) but does not bind IFNγ or IFNβ, enabling selective blockade of IFNα without affecting other type I interferons.
• Investigation of IFNα’s antiviral functions: By blocking IFNα in vivo, TIF3C5 helps define the contribution of this cytokine to viral clearance and host protection during infections such as chikungunya virus (CHIKV), lymphocytic choriomeningitis virus (LCMV), dengue virus (DENV), and others.
• Dissection of immune and inflammatory responses: The antibody is used to analyze how IFNα signaling shapes cytokine production, immune cell recruitment, and overall pathogenesis, thereby distinguishing the functions of IFNα from IFNβ in vivo.
• Preclinical studies on immunopathology: In mouse models, TIF3C5 blockade has been used to demonstrate that loss of IFNα signaling results in increased viral load, dissemination, and worsened clinical outcomes, reinforcing its key protective role.

Additional details:

• TIF3C5 is purified with low endotoxin levels, making it suitable for in vivo administration without inducing offtarget immune responses.
• The antibody has also been employed to study nonredundant functions of IFNα versus IFNβ by selectively blocking each cytokine in genetically modified mice.

Overall, TIF3C5 is a standard tool for in vivo functional blockade of mouse IFNα, routinely applied in infectious disease, immunology, and inflammation research where dissecting type I interferon biology is critical.

Commonly used antibodies or proteins employed with TIF3C5 (a monoclonal antibody targeting murine IFNα) in the literature include:

• HDβ4A7: This antibody specifically neutralizes murine IFNβ and is commonly used alongside TIF3C5 to differentiate the roles of IFNα versus IFNβ in experimental models.
• MAR15A3: An antiIFNAR1 (type I interferon receptor) monoclonal antibody, frequently used in parallel with TIF3C5 to achieve blockade of signaling from all type I interferons (both IFNα and IFNβ) by blocking their shared receptor.
• Isotype control antibodies: These are nonspecific control antibodies matching the isotype of TIF3C5, used to confirm that any observed effects are due to specific binding rather than general immunoglobulin effects.

Experimental context:

• These antibodies are often used together in studies investigating the distinct roles of type I interferons (IFNα vs. IFNβ) or to fully block type I IFN signaling in murine models, including infection (e.g., with West Nile virus), autoimmunity, and cancer immune response studies.
• TIF3C5 is specific to IFNα and does not bind murine IFNβ or IFNγ, so HDβ4A7 (for IFNβ) and MAR15A3 (for IFNAR1) are essential for direct comparison or comprehensive blockade.

Summary Table

References for these pairings and their experimental deployment:

• uses TIF3C5, HDβ4A7, and MAR15A3 to dissect type I IFN biology.
• notes MAR15A3 is often used with TIF3C5 for comprehensive inhibition of type I IFNs.
• describes experiments directly comparing TIF3C5 (IFNαspecific blockade) with MAR15A3.

Other proteins, such as cytokines (e.g., IFNγ) or genetically modified mice (e.g., IFNAR or IRF7 knockouts), are sometimes studied in parallel with these antibodies to further dissect signaling pathways, but the most common reagents paired with TIF3C5 are the antibodies listed above.

Clone TIF3C5 is a monoclonal antibody widely used in scientific research to specifically neutralize mouse interferonalpha (IFNα), and its key findings in the literature can be summarized as follows:

• Specificity and Selectivity: TIF3C5 binds specifically to several murine IFNα subtypes (e.g., IFNαA, 1, 4, 5, 11, 13), but it does not bind murine IFNβ or IFNγ. This makes it a valuable tool for dissecting the individual roles of IFNα in immune responses.

• Functional Role in Viral Infection Models:

  • TIF3C5 neutralizes the antiviral activity of IFNα in vitro and in vivo, allowing researchers to study the effects of IFNα deficiency.
  • In West Nile Virus (WNV) infection models, administration of TIF3C5 significantly increased mice's susceptibility and lethality, mimicking the phenotype of IFNαdeficient or IRF7knockout mice. This demonstrates a key antiviral role for IFNα during acute viral infection.
  • The lethality enhancement was statistically significant when TIF3C5 was delivered using a regimen of three administrations (compared to two), and the increased lethality was observed in both wildtype and IFNβdeficient mice.

• Role in Autoimmune and Inflammatory Models:

  • TIF3C5 has been used to selectively ablate IFNα activity in mouse models of type 1 diabetes, allowing for dissection of IFNα’s specific contributions to pathogenesis distinct from other type I interferons.
  • In checkpoint immunotherapy studies, antiIFNα (TIF3C5) was used to investigate the role of IFNα signaling in immune modulation and cancer therapy, although the blockade of IFNα did not always lead to improved immune or disease outcomes in certain settings, highlighting the contextdependent effects of type I IFNs.

• Tool for Dissecting Type I Interferon Biology:

  • By differentiating between IFNα and IFNβ effects, TIF3C5 has shown that these cytokines can have distinct, sometimes nonredundant roles in antiviral defense, immune regulation, and inflammation.
  • The neutralizing activity of TIF3C5 against different IFNα subtypes varies in potency, which may reflect differences in either binding affinity or the intrinsic activities of the individual subtypes.

• Technical Applications:

  • TIF3C5 is used in functional assays (in vitro and in vivo), ELISA, Western blotting, and as a neutralizing antibody in experimental animal models.
  • It is manufactured to high purity with low endotoxin levels, suitable for sensitive in vivo studies.

In summary: TIF3C5 has enabled researchers to define the exclusive contributions of IFNα (versus IFNβ or IFNγ) in murine models of infection, autoimmunity, and cancer, confirming that IFNα is crucial for antiviral defense and that its blockade can shift disease outcomes in ways reminiscent of genetic IFNα deficiency.

Should you need citations for specific disease models, mechanisms, or application protocols, please specify your area of interest.

Dosing regimens of clone TIF3C5, an antimouse IFNα monoclonal antibody, differ across mouse models depending on the disease context and experimental design, with doses typically ranging from 250 μg to 1 mg per injection and varying in number and timing of administrations within infection or tumor models. The most thoroughly documented regimens include single or multiple intraperitoneal (i.p.) injections, with precise timing tailored to the model and scientific question.

Key details from published studies include:

• West Nile Virus Infection Models:
  • Wildtype and knockout mice:
    • 500 μg TIF3C5 i.p. one day prior and two days after infection, or
    • 250 μg TIF3C5 i.p. one day prior, one day after, and three days after infection.
    • The threedose, lowermass regimen produced a more pronounced biological effect than the twodose, highermass regimen.
• Cancer Immunotherapy Models (e.g., AE17, AB1, Renca):
  • 1 mg TIF3C5 i.p., administered every third day for a total of three doses, starting three days after the initial immune checkpoint blockade (ICB) treatment.
• Chikungunya Virus Infection Models:
  • Wildtype mice were given 1 mg antimouse IFNα (TIF3C5) i.p. consistently, typically as a single dose, with direct comparison to IFNβ blockade and isotype controls.
• General Manufacturer Recommendations:
  • Leinco, a major supplier, notes that regimens vary and are adjusted based on disease model, mouse strain, experimental timing, and desired pharmacodynamic effect. Reported regimens typically fall within 250 μg–1 mg per injection, often repeated every 2–3 days during the early phase of infection or therapeutic intervention.

Adjustments are often made for:

• Mouse strain (e.g., wildtype vs. knockout).
• Disease type and severity.
• Timing relative to infection or therapy initiation.
• Desired depth and duration of IFNα blockade.

In summary: while common regimens range from 250 μg to 1 mg per dose administered i.p., precise protocols are customized to the disease model and experiment, mainly varying in dose, number, and spacing of injections.